Literature DB >> 18306214

Isolation and functional identification of a novel human hepatic growth factor: hepatopoietin Cn.

Chun-Ping Cui1, Da-Jin Zhang, Bing-Xing Shi, Shao-Jun Du, Dan-Li Wu, Ping Wei, Gen-Shen Zhong, Zi-Kuan Guo, Yang Liu, Li-Sheng Wang, Chu-Tse Wu.   

Abstract

UNLABELLED: Hepatic stimulating substance (HSS) was first isolated from weanling rat liver in 1975 and found to stimulate hepatic DNA synthesis both in vitro and in vivo. Since then, mammalian and human HSS have been investigated for their potential to treat hepatic diseases. However, the essential nature in composition and structure of HSS remain puzzling because HSS has not been completely purified. Heating, ethanol precipitation, and ion-exchange chromatographies had been carried out to isolate the protein with specific stimulating activity from newborn calf liver, and [(3)H]thymidine deoxyribose (TdR)/bromodeoxyuridine (BrdU) incorporation and carboxyfluorescein diacetate succinimidyl ester (CFSE)-based proliferation assay to determine the bioactivity in vitro and in vivo. We report the purification of a novel 30-kDa protein from a crude extract of calf liver HSS. This protein is a member of the leucine-rich acidic nuclear protein family (LANP) and has been named hepatopoietin Cn (HPPCn). Studies of partially hepatectomized (PH) mice show that levels of HPPCn messenger RNA (mRNA) increase after liver injury. Furthermore, the recombinant human protein (rhHPPCn) was shown to stimulate hepatic DNA synthesis and activate signaling pathways involved in hepatocyte proliferation in vitro and in vivo.
CONCLUSION: HPPCn is a novel hepatic growth factor that plays a role in liver regeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306214     DOI: 10.1002/hep.22126

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.

Authors:  Patrick T Reilly; Yun Yu; Ali Hamiche; Lishun Wang
Journal:  Bioessays       Date:  2014-08-25       Impact factor: 4.345

2.  Hepatic stimulator substance alleviates toxin-induced and immune-mediated liver injury and fibrosis in rats.

Authors:  Xuerui Yi; Ming Song; Youcheng Yuan; Xinrui Zhang; Wenyin Chen; Jin Li; Minghua Tong; Guangze Liu; Song You; Xiangping Kong
Journal:  Dig Dis Sci       Date:  2012-04-27       Impact factor: 3.199

3.  Production of hepatopoietin Cn in high-cell-density cultures of recombinant Escherichia coli and detection of its antioxygen activity.

Authors:  Yang Liu; Xiao-Li Li; Dong-Dong Zhang; Qiang Wang; Yong Liu; Dong-Mei Liu; Chu-Tse Wu; Chun-Ping Cui
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

4.  Involvement of hepatopoietin Cn in the development of human hepatocellular carcinoma.

Authors:  Bu-Dong Zhu; Xiao-Li Li; Yong Liu; Jing Chang; Yang Liu; Dong-Dong Zhang; Qiang Wang; Jun Ren; Chun-Ping Cui
Journal:  Clin Exp Metastasis       Date:  2010-08-04       Impact factor: 5.150

5.  Hepatopoietin Cn suppresses apoptosis of human hepatocellular carcinoma cells by up-regulating myeloid cell leukemia-1.

Authors:  Jing Chang; Yang Liu; Dong-Dong Zhang; Da-Jin Zhang; Chu-Tse Wu; Li-Sheng Wang; Chun-Ping Cui
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

6.  CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.

Authors:  Qian Cheng; Fuwen Yuan; Fengmin Lu; Bo Zhang; Tianda Chen; Xiangmei Chen; Yuan Cheng; Na Li; Liwei Ma; Tanjun Tong
Journal:  Oncotarget       Date:  2015-03-10

7.  Nucleostemin Knockdown Sensitizes Hepatocellular Carcinoma Cells to Ultraviolet and Serum Starvation-Induced Apoptosis.

Authors:  Fuwen Yuan; Qian Cheng; Guodong Li; Tanjun Tong
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

8.  Downregulation of ANP32B exerts anti-apoptotic effects in hepatocellular carcinoma.

Authors:  Yoshinori Ohno; Mitsuhito Koizumi; Hironao Nakayama; Takao Watanabe; Masashi Hirooka; Yoshio Tokumoto; Taira Kuroda; Masanori Abe; Shinji Fukuda; Shigeki Higashiyama; Teru Kumagi; Yoichi Hiasa
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.